Evidence-Based Diabetes Management > September 2019

Evidence-Based Diabetes Management - September 2019

September 25, 2019 – Jaime Rosenberg
Diabetes fully ripped my life and potential away. I always grew up thinking I would be a professional musician. I feel like I’m still mourning the loss of what my life would have been.”

--Sarah Tackett, age 26
September 25, 2019 – Jaime Rosenberg
The diagnosis of diabetes can be hard for a teenager to accept. Add insulin affordability to the mix, and by the time a young adult learns to live with the disease, the complications have already arrived.
September 26, 2019 – Andrew Smith
Aaron Kowalski, PhD, the new CEO of the JDRF, says in a discussion about insulin pricing that action is needed not only by Congress, but also by insulin makers, health plans, and the executive branch. The most important goal: ending a crosspayment scheme that many blame for potentially deadly price increases.
September 26, 2019 – Mary Caffrey
The results of a study published last year from authors at Yale Diabetes Center suggest that rationing is more common than the healthcare system wants to admit. Senior author Kasia Lipska, MD, MHS, says the findings raise a whole new set of questions.
September 26, 2019 – Mary Caffrey
A new concept for targeting insulin toward the liver could lead to people with diabetes needing less of it to control glycated hemoglobin (A1C) and avoid hypoglycemia.
September 27, 2019 – Kelly Davio
From the Center for Biosimilars®, a discussion of a regulatory change coming in 2020: Insulins have always been biologics from a scientific perspective, and the products themselves will not change as a result of bringing them under regulation as biologics as a matter of law. However, labeling for these products will change.
September 27, 2019 – Sara Karlovitch
From the Center for Biosimilars®, a discussion on giving patients new, less expensive alternatives for managing diabetes.
September 27, 2019 – Robert A. Gabbay, MD, PhD, FACP
The editor-in-chief of Evidence-Based Diabetes Management™ introduces the special issue, Perspectives on Insulin Pricing, and shares that he has seen rationing among his own patients. 
September 27, 2019 – Kyunghwa Park, PharmD; Angela Eng Jeong, PharmD; Eric Guenther-Gleason, PharmD, MS; and Sachin H. Jain, MD, MBA
Converting from analogue insulin to human insulin is associated with a clinical insignificant increase in glycated hemoglobin of 0.16% but with improved insulin adherence.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.